the product in the database has an inactive status
indications:
Supplementing and maintaining circulating blood volume in the case of volume loss symptoms, where the use of colloids is acceptable. The choice of albumin solution instead of artificial colloid solutions depends on the clinical condition of each patient, based on official recommendations.
Composition:
1 ml of solution contains 200 mg of total protein, including at least 96% of human albumin. The preparation contains 125 mmol / l of sodium ions.
Action:
The drug has a hyperonkotic effect. The 20% albumin solution has 4 times higher osmotic and oncotic properties than human plasma. Under normal circumstances, the albumin half-life is approximately 19 days. The elimination takes place mainly intracellularly thanks to lysosomal proteases. There are significant individual differences regarding the effect of albumin on the volume of plasma. In some patients, plasma volume may remain elevated for several hours after infusion. In critically ill patients, albumin can escape from the intravascular space in significant amounts at unpredictable rates.
Contraindications:
Hypersensitivity to albumin preparations or to any of the excipients.
Precautions:
Due to the possibility of excessive blood dilution or hypervolaemia, caution should be used in patients with: decompensated heart failure, hypertension, esophageal varices, pulmonary edema, hemorrhagic diathesis, severe anemia, renal or non-renal anuria. If clinical signs of cardiovascular overload (headache, dyspnoea, jugular vein overload) or increased blood pressure, increased central venous pressure or pulmonary edema occur, the infusion should be stopped immediately. When administering highly concentrated preparations of albumin, it is necessary to ensure that the patient's hydration level is sufficient. The patient should be carefully monitored to protect against circulatory overload and conduction. Suspicion of an allergic or anaphylactic reaction requires immediate interruption of the infusion; in the event of a shock, appropriate treatment should be applied. Despite the use of inactivation methods of infectious agents, the transfer of known and unknown pathogens can not be completely ruled out. When administering human albumin, one should monitor the concentration of electrolytes, and when it is necessary to replenish large volumes of liquids, hematocrit, parameters of the coagulation system, electrolytes, platelets and erythrocytes. Albumin solutions can not be diluted with water for injections, due to the risk of hemolysis of the patient's blood cells.
Pregnancy and lactation:
The safety of the preparation during pregnancy has not been established. Clinical experience in the use of human albumin suggests that no harmful effects on pregnancy, fetal or newborn development are expected. Human albumin is a natural component of human plasma.
Intravenous infusion: individual dosage - depending on the patient's weight, the severity of the injury or illness, and on the permanent loss of fluids and proteins. The volume of circulating blood (not plasma albumin) should be considered to determine the dose. Human albumin can be administered directly or after dilution in isotonic solution (eg in 5% Glucose or 0.9% NaCl solution) The concentration of albumin, infusion rate should be adjusted individually to the patient's condition and indications, while the plasma exchange rate should be adjusted to The following should be monitored before administration of human albumin: blood pressure, heart rate, central venous pressure, pulmonary wedge pressure, diuresis, electrolyte concentration, hematocrit / hemoglobin.
(C)
